SG11201912195TA - Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies - Google Patents

Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Info

Publication number
SG11201912195TA
SG11201912195TA SG11201912195TA SG11201912195TA SG11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA
Authority
SG
Singapore
Prior art keywords
synucleinopathies
formulations
alpha
treatment
terminal end
Prior art date
Application number
SG11201912195TA
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
United Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Neuroscience filed Critical United Neuroscience
Publication of SG11201912195TA publication Critical patent/SG11201912195TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
SG11201912195TA 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies SG11201912195TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521287P 2017-06-16 2017-06-16
PCT/US2018/037938 WO2018232369A1 (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
SG11201912195TA true SG11201912195TA (en) 2020-01-30

Family

ID=64659951

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912195TA SG11201912195TA (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Country Status (10)

Country Link
US (1) US20210138049A1 (enrdf_load_stackoverflow)
EP (1) EP3638298A4 (enrdf_load_stackoverflow)
JP (3) JP2021508672A (enrdf_load_stackoverflow)
KR (2) KR20200054938A (enrdf_load_stackoverflow)
AU (1) AU2018283510B2 (enrdf_load_stackoverflow)
BR (1) BR112019026707A2 (enrdf_load_stackoverflow)
CA (1) CA3067231A1 (enrdf_load_stackoverflow)
MX (1) MX2019015286A (enrdf_load_stackoverflow)
SG (1) SG11201912195TA (enrdf_load_stackoverflow)
WO (1) WO2018232369A1 (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
CN119409835A (zh) * 2017-10-27 2025-02-11 联脑科学公司 Tau肽免疫原构建体
KR20210110842A (ko) * 2018-12-28 2021-09-09 유나이티드 바이오메디칼 인크. 인터루킨 6(il-6)을 표적화하는 펩타이드 면역원 및 il-6 조절장애에 의해 영향을 받는 질환의 면역요법을 위한 이의 제형
BR112022023366A2 (pt) 2020-05-19 2023-05-02 Othair Prothena Ltd Vacina com múltiplos epítopos para o tratamento de mal de alzheimer
WO2022029181A1 (en) * 2020-08-04 2022-02-10 Ac Immune Sa Immunogenic compounds
MX2023003007A (es) * 2020-09-17 2023-04-10 Prothena Biosciences Ltd Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias.
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
WO2022265091A1 (ja) 2021-06-18 2022-12-22 住友ファーマ株式会社 ヒトαシヌクレインのエピトープペプチド及び該ペプチドを含む医薬組成物
AU2022337284A1 (en) * 2021-09-01 2024-03-21 Vaxxinity, Inc. Methods for the prevention and treatment of synucleinopathies
CN119053345A (zh) 2022-02-28 2024-11-29 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US20120142902A1 (en) * 2007-02-23 2012-06-07 The Regents Of The University Of California Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
JP5810413B2 (ja) * 2008-12-19 2015-11-11 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗アルファシヌクレイン自己抗体
US12156912B2 (en) * 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
CA2885924C (en) * 2012-08-21 2022-12-13 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
WO2015157117A2 (en) * 2014-04-09 2015-10-15 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
US10155030B2 (en) * 2014-05-23 2018-12-18 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease

Also Published As

Publication number Publication date
CA3067231A1 (en) 2018-12-20
JP2025090637A (ja) 2025-06-17
US20210138049A1 (en) 2021-05-13
RU2020101121A (ru) 2021-07-16
EP3638298A4 (en) 2021-05-05
WO2018232369A1 (en) 2018-12-20
BR112019026707A2 (pt) 2020-06-30
JP2021508672A (ja) 2021-03-11
KR20240150813A (ko) 2024-10-16
MX2019015286A (es) 2020-08-17
JP7732676B2 (ja) 2025-09-02
AU2018283510B2 (en) 2025-06-26
AU2018283510A1 (en) 2020-01-16
RU2020101121A3 (enrdf_load_stackoverflow) 2021-10-15
KR20200054938A (ko) 2020-05-20
JP2023082018A (ja) 2023-06-13
EP3638298A1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
SG11201912195TA (en) Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
IL322464A (en) Methods and compositions for administering therapeutic protein
IL275777A (en) Improved peptide drugs for the treatment of NASH and other disorders
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
HUE057083T2 (hu) C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
ZA201905851B (en) Peptides and methods for the treatment of diabetes
EP3829597A4 (en) TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION
IL290520A (en) Medicinal peptides
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
IL285144A (en) Medicinal peptides
HUE059500T2 (hu) Aminosavakat tartalmazó készítmények elhízás kezelésében történõ alkalmazásra
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
ZA202100587B (en) Peptide compounds and therapeutic uses of same
IL282519A (en) Peptide fragments for the treatment of diabetes
IL277734A (en) Application of short PEDF-derived peptides in the treatment of osteoarthritis
IL275690A (en) Nanoparticles for targeted delivery of therapeutic polypeptides
ZA202100880B (en) Short cyclic peptides for the treatment of graves' disease
PL3416677T3 (pl) Kompozycja farmaceutyczna obejmująca rekombinowany hgh do leczenia niedoboru hormonu wzrostu
IL280066A (en) Injection techniques to treat cellulite
SG11202106847SA (en) Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
EP3628048A4 (en) PEPTIDES FOR CANCER TREATMENT
IL281091A (en) Peptide therapy for cancer treatment and their uses
IL276824A (en) Compositions and methods for administration and expression of small inhibitory peptides and their use
GB201809742D0 (en) Therapeutic Delivery Vectors